Abstract:In a 2×2 crossover trial for establishing average bioequivalence (ABE) of a generic agent and a currently marketed drug, the recommended approach to hypothesis testing is the two one-sided test (TOST) procedure, which depends, among other things, on the estimated within-subject variability. The power of this procedure, and therefore the sample size required to achieve a minimum power, depends on having a good estimate of this variability. When there is uncertainty, it is advisable to plan the design in two stages, with an interim sample size reestimation after the first stage, using an interim estimate of the within-subject variability. One method and 3 variations of doing this were proposed by Potvin et al. Using simulation, the operating characteristics, including the empirical type I error rate, of the 4 variations (called Methods A, B, C, and D) were assessed by Potvin et al and Methods B and C were recommended. However, none of these 4 variations formally controls the type I error rate of falsely claiming ABE, even though the amount of inflation produced by Method C was considered acceptable. A major disadvantage of assessing type I error rate inflation using simulation is that unless all possible scenarios for the intended design and analysis are investigated, it is impossible to be sure that the type I error rate is controlled. Here, we propose an alternative, principled method of sample size reestimation that is guaranteed to control the type I error rate at any given significance level. This method uses a new version of the inverse-normal combination of p-values test, in conjunction with standard group sequential techniques, that is more robust to large deviations in initial assumptions regarding the variability of the pharmacokinetic endpoints. The sample size reestimation step is based on significance levels and power requirements that are conditional on the first-stage results. This necessitates a discussion and exploitation of the peculiar properties of the power curve of the TOST testing procedure. We illustrate our approach with an example based on a real ABE study and compare the operating characteristics of our proposed method with those of Method B of Povin et al.

EXPLORATION THE POTENTIAL IMPACT OF BATCH-TO-BATCH VARIABILITY OF INHALATION POWDER DRUG PRODUCTS ON PHARMACOKINETIC BIOEQUIVALENCE STUDY POWER.

Pharmacokinetic Models for Inhaled Fluticasone Propionate and Salmeterol Xinafoate to Quantify Batch-to-Batch Variability

A Bioequivalence Approach for Generic Narrow Therapeutic Index Drugs: Evaluation of the Reference-Scaled Approach and Variability Comparison Criterion

Bioequivalence requirements for orally inhaled and nasal drug products and use of novel physiologically based biopharmaceutics modeling approaches for assessing in vivo performance

Bioequivalence of Two Tiotropium Dry Powder Inhalers and the Utility of Realistic Impactor Testing

Pharmacokinetic Bioequivalence between Generic and Originator Orally Inhaled Drug Products: Validity of Administration of Doses above the Approved Single Maximum Dose

Determining Equivalence for Generic Locally Acting Drug Products

In Vitro Bioequivalence Testing.

Physiologically Based Pharmacokinetics Modeling in Biopharmaceutics: Case Studies for Establishing the Bioequivalence Safe Space for Innovator and Generic Drugs

Pharmacogenetic perspectives in improving pharmacokinetic profiles for efficient bioequivalence trials with highly variable drugs: a review

Sample size determination and post hoc statistical power in bioequivalence studies

Controlling the type I error rate in two-stage sequential adaptive designs when testing for average bioequivalence

Prediction of pharmacokinetic parameters of inhaled indacaterol formulation in healthy volunteers using physiologically-based pharmacokinetic (PBPK) model

Comparative Analyses of Bioequivalence Assessment Methods for In Vitro Permeation Test Data

Power Analysis and Sample Size Determination for Crossover Trials with Application to Bioequivalence Assessment of Topical Ophthalmic Drugs Using Serial Sampling Pharmacokinetic Data

Pharmacokinetic Properties and Bioequivalence of Orally Inhaled Salbutamol in Healthy Chinese Volunteers.

Influence of Formulation Factors on the Aerosol Performance of Suspension and Solution Metered Dose Inhalers: A Systematic Approach

Pharmacokinetic And Bioequivalence Study Of Three Oral Formulations Of Ambroxol 30 Mg: A Randomized, Three-Period Crossover Comparison In Healthy Volunteers

An Adaptive Three‐Arm Comparative Clinical Endpoint Bioequivalence Study Design With Unblinded Sample Size Re‐Estimation and Optimized Allocation Ratio

Alternative Analysis Approaches for the Assessment of Pilot Bioavailability/Bioequivalence Studies

Advantage Of A Population Pharmacokinetic Method For Evaluating The Bioequivalence And Accuracy Of Parameter Estimation Of Pidotimod